Detalhe da pesquisa
1.
Baseline Tumor Size as Prognostic Index in Patients With Advanced Solid Tumors Receiving Experimental Targeted Agents.
Oncologist
; 29(1): 75-83, 2024 Jan 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37548439
2.
Adjuvant Olaparib for Germline BRCA Carriers With HER2-Negative Early Breast Cancer: Evidence and Controversies.
Oncologist
; 28(7): 565-574, 2023 07 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37210568
3.
Refining risk stratification in HR-positive/HER2-negative early breast cancer: how to select patients for treatment escalation?
Breast Cancer Res Treat
; 192(3): 465-484, 2022 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-35124720
4.
Systemic Treatment of Ductal Carcinoma In Situ of the Breast.
Chirurgia (Bucur)
; 116(5 Suppl): S97-S104, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34967317
5.
Pretreatment Blood Parameters Predict Efficacy from Immunotherapy Agents in Early Phase Clinical Trials.
Oncologist
; 25(11): e1732-e1742, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32785940
6.
Next Generation Sequencing (NGS): A Revolutionary Technology in Pharmacogenomics and Personalized Medicine in Cancer.
Adv Exp Med Biol
; 1168: 9-30, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31713162
7.
Fluorouracil and dose-dense adjuvant chemotherapy in breast cancer: lessons learned from the 20-year-old GIM2 trial.
Lancet Oncol
; 23(12): 1482-1484, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36370715
8.
Eribulin across multiple lines of chemotherapy: a retrospective study on quality of life and efficacy in metastatic breast cancer patients.
Future Oncol
; 13(11s): 11-23, 2017 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-28481185
9.
Editorial: Optimizing treatment strategy in early breast cancer: less is more, or more is better?
Curr Opin Oncol
; 31(6): 469-471, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31464761
10.
PARP Inhibitors for Breast Cancer Treatment: A Review.
JAMA Oncol
; 10(5): 658-670, 2024 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38512229
11.
Evolution of HER2 expression between pre-treatment biopsy and residual disease after neoadjuvant therapy for breast cancer.
Eur J Cancer
; 201: 113920, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38368741
12.
Clinicopathological characteristics and eligibility for adjuvant olaparib of germline BRCA1/2 mutation carriers with HER2-negative early breast cancer.
NPJ Breast Cancer
; 10(1): 28, 2024 Apr 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-38627457
13.
Prevalence, Dynamics, and Prognostic Role of Clonal Hematopoiesis of Indeterminate Potential in Patients With Breast Cancer.
J Clin Oncol
; : JCO2301071, 2024 Jan 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38190580
14.
Role of Immunotherapy in Early- and Late-Stage Triple-Negative Breast Cancer.
Hematol Oncol Clin North Am
; 37(1): 133-150, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36435606
15.
Next-generation antibody-drug conjugates for breast cancer: Moving beyond HER2 and TROP2.
Crit Rev Oncol Hematol
; 190: 104090, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37562695
16.
Liquid biopsy for brain metastases and leptomeningeal disease in patients with breast cancer.
NPJ Breast Cancer
; 9(1): 43, 2023 May 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-37225714
17.
Clinicopathological features and survival outcomes of luminal-like breast tumors with estrogen receptor loss at metastatic recurrence: A case-control study.
Eur J Cancer
; 195: 113397, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37890353
18.
Emerging Targeted Therapies for Early Breast Cancer.
Drugs
; 82(14): 1437-1451, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-36207645
19.
Loss of HER2 in breast cancer: biological mechanisms and technical pitfalls.
Cancer Drug Resist
; 5(4): 971-980, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36627895
20.
Targeting HER2 in breast cancer: new drugs and paradigms on the horizon.
Explor Target Antitumor Ther
; 2(2): 139-155, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-36046143